Theraheart is a technology company.
Theraheart has raised $21.0M across 1 funding round.
Theraheart has raised $21.0M in total across 1 funding round.
Theraheart has raised $21.0M in total across 1 funding round.
Theraheart's investors include Kevin, Qiming Venture Partners.
Theraheart Inc. is a medical device company based in Irvine, California, developing innovative, minimally invasive technologies to treat heart failure, a condition affecting 1 in 4 people over their lifetime with only 52% five-year survival and ~$100B annual U.S. healthcare costs.[2] The company builds implantable cardiac devices, such as shunting catheters with expandable elements, to assist patients with advanced heart failure by improving blood flow and reducing symptoms like shortness of breath, fatigue, swelling, and chest pain.[2][5][6] It serves heart failure patients and healthcare providers, addressing the critical need for breakthrough solutions amid frequent hospitalizations; growth momentum includes incorporation in 2023, a $20.6M Series A in 2025, and additional $11.6M in Series A-1v/A-2 tranches, plus U.S. patents signaling clinical advancement.[3][4][5][6]
Theraheart was officially incorporated as a stock corporation on February 21, 2023, in Delaware and registered in California, with operations at 16 Technology Drive Suite 202, Irvine, CA.[4] Founded by Wei Gan, Ph.D., who serves as CEO, CFO, and Secretary, the company draws from a team of passionate engineers including Director of Engineering Rani Mahmoudi (patent inventor for shunting catheter tech) and Sr. Director of Clinical Jean-Pierre M. Rabbah, Ph.D.[2][4][6] The idea emerged from their diverse backgrounds in engineering and cardiac health, uniting to tackle heart failure's unmet needs through minimally invasive implants; early traction includes rapid Series A funding post-incorporation and securing U.S. Patent 12,376,879 in August 2025 for expandable shunting elements.[3][5][6]
Theraheart rides the wave of medtech innovation in cardiovascular care, where heart failure's rising prevalence—driven by aging populations and post-COVID cardiac complications—demands next-gen implants over pharmaceuticals alone.[2] Timing is ideal amid surging VC interest in healthcare devices, as seen in their $20.6M+ Series A amid top-10 U.S. raises for the sector in late 2025, fueled by market forces like $100B+ costs and low survival rates pushing for cost-saving, minimally invasive alternatives.[2][3][5] It influences the ecosystem by advancing shunting tech (e.g., patents for expandable catheters), potentially lowering rehospitalization rates and inspiring peer innovation in cardiac assist devices.[1][6]
Theraheart is poised for pivotal clinical trials and FDA pathways, leveraging its $32M+ funding and IP to commercialize shunts amid booming demand for heart failure solutions.[3][5][6] Trends like AI-enhanced device design and value-based care will accelerate adoption, potentially expanding influence through partnerships or acquisitions as survival stats improve. With its engineering-driven origins targeting a lifelong epidemic, Theraheart exemplifies how focused medtech innovators can transform cardiac outcomes.[2]
Theraheart has raised $21.0M across 1 funding round. Most recently, it raised $21.0M Series A in October 2025.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Oct 1, 2025 | $21.0M Series A | Kevin, Qiming Venture Partners |